West Michigan Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.09M Hold
2,274
0.46% 64
2026
Q1
$2.09M Buy
2,274
+120
+6% +$122K 0.46% 64
2025
Q4
$2.31M Sell
2,154
-527
-20% -$504K 0.53% 65
2025
Q3
$2.05M Buy
2,681
+201
+8% +$150K 0.49% 66
2025
Q2
$1.93M Sell
2,480
-160
-6% -$124K 0.55% 46
2025
Q1
$2.18M Buy
2,640
+13
+0.5% +$10.8K 0.72% 39
2024
Q4
$2.03M Buy
2,627
+5
+0.2% +$4.14K 0.61% 41
2024
Q3
$2.32M Buy
2,622
+46
+2% +$41.4K 0.7% 40
2024
Q2
$2.33M Buy
2,576
+34
+1% +$27.2K 0.74% 36
2024
Q1
$1.98M Sell
2,542
-58
-2% -$41.3K 0.64% 40
2023
Q4
$1.52M Buy
2,600
+20
+0.8% +$11.7K 0.57% 42
2023
Q3
$1.39M Buy
2,580
+2
+0.1% +$1.03K 0.74% 40
2023
Q2
$1.21M Sell
2,578
-64
-2% -$26.8K 0.48% 58
2023
Q1
$907K Buy
2,642
+137
+5% +$46.2K 0.52% 46
2022
Q4
$916K Sell
2,505
-8
-0.3% -$2.84K 0.67% 35
2022
Q3
$813K Sell
2,513
-2
-0.1% -$634 0.71% 35
2022
Q2
$815K Sell
2,515
-1
-0% -$300 0.7% 39
2022
Q1
$721K Buy
2,516
+113
+5% +$29.1K 0.49% 46
2021
Q4
$664K Buy
+2,403
New +$609K 0.49% 47

Other funds holding LLY

West Michigan Advisors's LLY Position: Q2 2026 in Review

West Michigan Advisors held its Eli Lilly (LLY) position steady in Q2 2026 at 2,274 shares worth $2.09M. The position accounts for 0.46% of the portfolio, ranked #64.

West Michigan Advisors first reported a position in LLY in Q4 2021 and has held it in 19 quarters since. The position peaked at $2.33M in Q2 2024. 1,912 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • West Michigan Advisors held 2,274 shares of Eli Lilly worth $2.09M as of Q2 2026.
  • West Michigan Advisors left its Eli Lilly share count unchanged in Q2 2026.
  • Eli Lilly made up 0.46% of West Michigan Advisors's portfolio in Q2 2026, its #64 holding.
  • West Michigan Advisors first reported a position in Eli Lilly in Q4 2021 and has held it in 19 quarters since.
  • West Michigan Advisors's Eli Lilly position peaked at $2.33M in Q2 2024.
  • 1,912 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on West Michigan Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.